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Data from dietary intervention studies suggest that intake of (−)-epicatechin mediates beneficial 
vascular effects in humans. However, population-based investigations are required to evaluate 
associations between habitual intake and health and these studies rely on accurate estimates of 
intake, which nutritional biomarkers can provide. Here, we evaluate a series of structurally related 
(−)-epicatechin metabolites (SReM), particularly (−)-epicatechin-3′-glucuronide, (−)-epicatechin-
3′-sulfate and 3′-o-methyl-(−)-epicatechin-5-sulfate (SREMB), as flavan-3-ol and (−)-epicatechin 
intake. SReMB in urine proved to be a specific indicator of (−)-epicatechin intake, showing also a strong 
correlation with the amount of (−)-epicatechin ingested (R2: 0.86 (95% CI 0.8l; 0.92). The median 
recovery of (−)-epicatechin as SReMB in 24 h urine was 10% (IQR 7–13%) and we found SREMB in 
the majority of participants of EPIC Norfolk (83% of 24,341) with a mean concentration of 2.4 ± 3.2 
µmol/L. our results show that SReMB are suitable as biomarker of (−)-epicatechin intake. According to 
evaluation criteria from iARc and the institute of Medicine, the results obtained support use of SReMB 
as a recovery biomarker to estimate actual intake of (−)-epicatechin.
There is considerable evidence suggesting that flavanols can be beneficial for cardiovascular disease prevention 
and health maintenance, although current data are still insufficient to provide general dietary guidance1,2. Recent 
data have shown that the monomer (−)-epicatechin, but not oligomeric and polymeric procyanidins, are respon-
sible for improvements in vascular function3. While the effect of (−)-epicatechin on health can be investigated in 
clinical dietary intervention studies, only epidemiological investigations can provide population-based informa-
tion about the long-term effect of (−)-epicatechin as part of the habitual diet. However, such investigations rely 
on an accurate estimate of intake, and this is not possible with the methods commonly used today. Reasons lie in 
the significant limitation of self-reported dietary data as well as in the large variability of the (−)-epicatechin con-
tent of foods (Table 1). Alternatives to the latter approach emerge in the use of nutritional biomarkers of intake, 
which reflect actual intake and do not rely on self-reported food intakes and food composition data4,5. While we 
have recently evaluated a nutritional biomarker of flavan-3-ol intake6, there are currently no established biomark-
ers to specifically assess the intake of (−)-epicatechin.
Nutritional biomarkers for phenolic compounds such as (−)-epicatechin, are often based on the concentra-
tion of their metabolites in blood or urine7. However, a careful evaluation of phenolic metabolites is important 
to assess their suitability and to identify their strengths and limitations as biomarkers of intake. Previously, we 
used the evaluation process proposed by IARC (International Agency for Research on Cancer) and the IOM 
(Institute of Medicine)6 to evaluate 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (gVL) and its metabolites (gVLM) 
as nutritional biomarker of flavan-3-ol intake6. These criteria include: (i) demonstration of accuracy, precision 
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and reliability of the analytical method to quantify the candidate biomarker; (ii) demonstration and charac-
terization of the relationship between intake and candidate biomarker levels in urine, including characterizing 
specificity and intra-individual variability; and (iii) demonstration of the applicability of the candidate bio-
marker to estimate intake in large cohort studies. Here, we apply the same criteria to evaluate three of the most 
abundant structurally related (−)-epicatechin metabolites (SREM), including (−)-epicatechin-3′-glucuronide 
(E3′G), (−)-epicatechin-3′-sulfate (E3′S) and 3′-O-methyl-(−)-epicatechin-5-sulfate (3MeE5S), as biomarker of 
(−)-epicatechin intake and to estimate (−)-epicatechin intake in large-scale cohort studies using this biomarker.
Methods
Analytical method – epidemiological study. Analysis was performed using ultra high-performance 
liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS; Waters Acquity BSM, coupled 
with an Applied Biosystems API 4000; see Supplemental Fig. 1 for a typical chromatogram). De novo synthe-
sized authentic standards8,9 of three human structurally related epicatechin metabolites (SERMs) considered 
in this study ((−)-epicatechin-3′-glucuronide (E3′G), (−)-epicatechin-3′-sulfate (E3′S) and 3′-O-methyl-(−)-
epicatechin-5-sulfate (3Me5S)), as well as stable isotope labelled internal standards (ISTD, D2/D3-epicatechin-
3′-β-D-glucuronide, 50:50 mix) were obtained from Analyticon (Analyticon Technologies AG, Lichtenfels, 
Germany; Supplemental Fig. 2 for structures). Purity was assessed by LC-UV and LC-MS, and stock solutions 
were adjusted accordingly. Stock solutions were prepared in ethanol:water (70:30, v/v) and stored at −80 °C.
Flavan-3-ol metabolite-free spot urine was obtained from human volunteers on a low-flavan-3-ol diet, 
excluding in particular tea, pome fruits and berries from their diet. This study was approved by the University 
of Reading Research Ethics Committee. All participants gave their written informed consent to participate and 
all experiments were performed in accordance with relevant University guidelines and regulations and followed 
GCP (good clinical practice).
Urine samples (60 µL) and internal standard solutions (1.0 µM ISTD, 60 µL) were combined, filtered (Impact 
Protein Precipitation filter plate, Phenomenex, Macclesfield, UK) by centrifugation (500 × g) for 2 minutes at 
room temperature and stored at −20 °C until analysis. Sample preparation was automated for the analysis of EPIC 
(European Prospective Investigation into Cancer) Norfolk cohort urine samples using a Hamilton Star robot 
(Hamilton, Bonaduz, Switzerland).
Samples were separated by liquid chromatography (Acquity, Waters, Elstree, UK) using a C18 column 
(Kinetex C18 100 × 2.1 mm, 1.7 µm, with 0.5 µm Krudcatcher, Phenomenex, Macclesfield, UK). Gradient elution 
was performed at a flow rate of 0.5 mL/min using 0.1% formic acid in water as mobile phase A and acetonitrile/
methanol (9:1, v/v) as mobile phase B. The initial starting conditions were 95% A, which were held for 2 min, 
decreasing to 85% A at 3.5 min, 79.6% at 6.0 minutes 5% A at 6.1 minutes and held until 7.0 minutes to wash the 
column before returning to 95% A at 7.1 minutes for re-equilibration until 8 minutes. The column temperature 
was maintained at 25 °C and the injection volume was 10 µL.
Compounds were detected using an Applied Biosystems Sciex API 4000 instrument (Warrington, UK) 
equipped with Turbo Ion Spray probe operating in negative ion mode using the parameters shown in Table 2. The 
spray voltage was −4500 V and the source temperature was 600 °C. The dwell time was 20 ms for each transition.
Samples quantified using calibration standards prepared in flavan-3-ol metabolite-free urine samples (stand-
ard concentrations [µM] were prepared at 0.1, 0.25, 1, 2, 3, 4, 5). E3′G, E3′S and 3Me5S were quantified using the 
peak area ratio of analyte and ISTD (D2/D3-E3′G, 50:50 (w/w), where the D3-E3′G precursor/product ions were 
used).
Food Content [mean ± SD, range]
Apple (Cider), peeled 28.7 ± 26.5 (0.0–141.0)
Apple (Dessert), peeled 6.7 ± 4.5 (0.0–19.8)
Apricot, raw 3.5 ± 4.3 (0.0–6.1)
Blackberry, raw 11.5 ± 10.9 (2.7–18.1)
Chocolate, dark 70.4 ± 29.5 (32.7–125.0)
European cranberry 4.2 ± 0.0 (4.2–4.2)
Grape (Black) 5.2 ± 5.6 (0.7–8.6)
Nectarine, peeled 3.0 ± 1.1 (1.3–5.6)
Peach, peeled 8.0 ± 4.2 (0.7–16.5)
Pear, whole 3.8 ± 2.7 (0.2–7.5)
Red raspberry, raw 5.0 ± 3.8 (0.3–8.3)
Sweet cherry, raw 7.8 ± 2.9 (5.5–9.5)
Tea (Black), infusion 3.9 ± 4.3 (0.0–16.8)
Tea (Green), infusion 7.9 ± 13.7 (0.0–73.9)
Tea (Oolong), infusion 2.7 ± 3.8 (0.0–13.2)
Wine (Red) 3.8 ± 3.2 (0.0–16.5)
Table 1. Ranges of (−)-epicatechin content (mg/100 g or mg/100 mL) of different foods commonly consumed 
(data from Phenol Explorer 3.037).
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Each batch included two replicates of quality control (QC) samples with three different concentrations; low 
QC (0.3 µM), medium QC (2.5 µM) and high QC (3.8 µM). Usual acceptance criteria for each batch were that as 
least one QC at each concentration and four out of the six QCs were within 15% of the theoretical concentration.
The method was validated using flavan-3-ol metabolite-free urine, spiked with the authentic standards 
E3′G, E3′S and 3Me5S to assess stability, specificity, matrix effects, precision and accuracy. The matrix effect was 
assessed by spiking flavan-3-ol metabolite-free urines from different sources with known amounts of analyte and 
internal standard and comparing their peak-area-ratio ratios. Method performance was assessed using data from 
quality control samples in 255 batches analyzed.
Human intervention studies. Three human intervention studies were conducted to investigate biomarker 
specificity, intake-response relationship and intra-individual variability. Details of the human intervention stud-
ies, with the exception of the investigation of intra-individual variability, have been described previously6. Briefly, 
the intervention consisted of fruit-flavoured non-dairy drinks that contained either specific flavan-3-ols (specific-
ity study) or varying amounts of flavan-3-ols derived from cocoa (4 levels for the intake amount escalation study) 
and chocolate-flavored dairy drinks containing flavan-3-ols derived from cocoa (intra-variability study). The 
test materials were prepared freshly each day, and were matched regarding their macro- and micronutrient con-
tent and orosensory and physicochemical characteristics. All test materials were supplied by Mars, Incorporated 
(McLean, VA). A summary of the events taking during each study visit is summarized in Supplemental Fig. 3. 
These study protocols were approved by the Institutional Review Board of UC Davis. All participants gave their 
written informed consent to participate and all experiments were performed in accordance with local guidelines 
and regulations. These studies were registered as NCT03194620 and NCT03201822.
Study population. Healthy adults between 25 and 60 years of age (specificity study, Supplemental Fig. 4) and 
between 25 and 40 years of age (intake amount escalation study, Supplemental Fig. 5) were recruited by public 
advertisement in the city of Davis and surrounding areas (California, USA). Exclusion criteria were previously 
described as: body mass index (BMI) higher than 30 kg/m2, blood pressure (BP) higher than 140/90 mmHg, food 
allergies to test materials and a history of disease6. Throughout participation in the study (approximately, 8 weeks 
for the Specificity study, 4 weeks for the Intake escalation study and 2 weeks for the Intra-individual variability 
study), volunteers were asked to maintain their typical daily activities and diet. To control for potential dietary 
flavan-3-ol intake, volunteers were asked to follow a defined low-flavan-3-ol diet on the day prior to and during 
each study day, for a total of 2 days following a low-flavan-3-ol diet. All volunteers were instructed on how to 
follow a low-flavan-3-ol diet, receiving foods containing low or negligible amounts of flavanols including the 
dinner for the night previous to the study day. Volunteers were required to fast overnight (12 h water, ad libitum) 
before each study day.
Specificity study. In order to investigate the specificity of SREMB as nutritional biomarker of flavan-3-ol intake, 
we performed a randomized, double-masked and 8×-crossover dietary intervention study with different possi-
ble precursors of structurally related (−)-epicatechin metabolites in healthy male adults (n = 12). Details of this 
study have been reported previously6. The flavan-3-ols tested were: (i) (–)-epicatechin, (ii) (−)-epigallocatechin, 
(iii) (−)-epicatechin-3-O-gallate, (iv) (−)-epigallocatechin-3-O-gallate (all compounds isolated from green 
tea, purity >99% and food grade), (v) a 1:1:1: mixture of theaflavin-3-O-gallate, theaflavin-3′-O-gallate and 
theaflavin-3,3′-O-digallate, (vi) thearubigins (all isolated from black tea, purity >95% and food grade) and (vii) 
procyanidin B-2 ((−)-epicatechin-(4α4β)-(−)-epicatechin; isolated from cocoa, purity 91%). One additional visit 
included the consumption of the test material without any flavan-3-ol added (control day). The amount of flavan-
3-ols consumed per volunteer per study visit was equivalent to 34.8 mg or 120 µmol, which is close to the mean 
intake amount of (–)-epicatechin consumed in the UK10. Test materials were consumed on a single occasion in 
the morning of the study visit. After intake, urine was collected over 24 h in two collection periods (from 0 h to 
6 h post intake and 6 h to 24 h post intake), using a fresh container for each collection period with 20 mL of 2 M 
sodium acetate (pH = 4.5) and 2 mL of 0.5% (w/v) thymol in isopropanol as preservatives. Volunteers returned 
containers upon completion of sample collection, and urine was stored at −80 °C until analysis. Volunteers were 
randomized to receive the 8 different test materials using computer-generated lists of random numbers via the 
randomly permuted block method. Study visits were separated by approximately 7 days for most volunteers, but 
never less than 3 days. The allocation list was generated by a researcher not involved with the recruitment and 
allocation of participants. Participants, study nurses, and researchers assessing outcomes as well as researchers 
involved with the statistical analysis of data were masked to the specific nature of intervention. The initial recruit-
ment started in August 2016, and the study was conducted from August 2016 to January 2017.
Analyte
Precursor ion 
(m/z)
Product ion 
(m/z)
Retention 
time (min)
(−)-epicatechin-3′-glucuronide (E3′G) 464.8 289.1 4.2
(−)-epicatechin-3′-sulfate (E3′S) 369.1 289.1 4.3
3′-O-methyl-(−)-epicatechin-5-sulfate (3Me5S) 382.9 303.1 4.6
D2-epicatechin-3′-β-D-glucuronide (D2-E3′G) 466.6 291.1 4.1
D3-epicatechin-3′-β-D-glucuronide (D3-E3′G) 468.3 292.1 4.1
Table 2. LC-MS parameters for analytes and internal standards considered in method including precursor and 
product ions (m/z) and typical retention times.
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Intake escalation study. In order to investigate the association between flavan-3-ol intake and SREMB excre-
tion, we conducted a dietary intervention study where participants consumed different amounts of flavan-3-ol. 
Details of this study have been reported previously6. This was a randomized, double-masked study and followed 
a 4×-crossover design, in which healthy male adults (n = 14) consumed four different amounts of flavan-3-ols 
that ranged from 95 mg to 1424 mg, including 15 mg to 227 mg of (−)-epicatechin, which are amounts including 
and exceeding the range of intakes determined in the UK10. Test materials were consumed on a single occasion 
in the morning of the study visit. After intake, urine was collected over 24 h in 4 collection periods (from 0 h to 
4 h post intake, 4 h to 8 h post intake, 8 h to 12 h post intake and 12 h to 24 h post intake), using a fresh container 
for each collection period with 20 mL of 2 M sodium acetate (pH = 4.5) and 2 mL of 0.5% (w/v) thymol in iso-
propanol as preservatives. Volunteers returned the container upon completion of sample collection, and urine 
was stored at −80 °C until analysis. Volunteers were randomized to receive the four different test materials using 
computer-generated lists of random numbers via the randomly permuted block method. Study visits were sepa-
rated by approximately 7 days for most volunteers, but never fewer than 3 days. The allocation list was generated 
by a researcher not involved with the recruitment and allocation of participants. Participants, study nurses, and 
researchers assessing outcomes as well as researchers involved with the statistical analysis of data were masked to 
the intervention. The initial recruitment started in April 2013, and the study was conducted from April to May 
2013.
Intra-individual variability study. In order to investigate the intra-individual variation of SREMB excre-
tion, we conducted a dietary intervention study where male and female participants consumed the same 
flavan-3-ol-containing drink on two different occasions separated by not less than 3 days (for study population 
see Supplemental Fig. 6). The amount of flavan-3-ols ingested was 542 mg, including 76 mg of (−)-epicatechin, 
which is well within the range of intakes determined in the UK10. Test materials were consumed on a single occa-
sion in the morning of the study visit. After intake, urine was collected over 24 h in 2 collection periods (from 0 h 
to 6 h post intake and 6 h to 24 h post intake), using a fresh container for each collection period with 20 mL of 2 M 
sodium acetate (pH = 4.5) and 2 mL of 0.5% (w/v) thymol in isopropanol as preservatives. Volunteers returned 
the container upon completion of sample collection, and urine was stored at −80 °C until analysis. Study visits 
were separated by approximately 7 days for most volunteers, but never less than 3 days. The initial recruitment 
started in July 2018, and the study was conducted from August to September 2018.
Analytical method – human intervention studies. Urine samples from human intervention studies (50 µL) were 
diluted with 100 µL of 100 µM 3-methyl hippuric acid (internal standard) and analyzed by UPLC-MS within 24 h, 
using a method described previously6. Samples were separated on a Waters Acquity UPLC (Waters, Milford, MA, 
USA) with an autosampler cooled at 5 °C. The injection volume was 37.5 µL. Chromatography was carried out at 
25 °C using a 100 × 2.1 mm Kinetex C18 1.7 µm, reversed phase column with a Krudcatcher (Phenomenex). The 
mobile phase, pumped at a flow rate of 0.5 mL/min, was (A) 5 mM ammonium formate (pH 2.9); and (B) acetoni-
trile/methanol (90:10, v/v). The gradient started with 5% B from 0–2 min, then ramped to 17.5% from 2–3.5 min, 
and then to 22.5% from 3.5–6 min. Detection was achieved with a Waters Micromass Quattro Premier spectrom-
eter fitted with an electrospray interface (ESI; Waters). MS analysis was carried out in negative ionization mode by 
multiple reaction monitoring (MRM). Detection of (−)-epicatechin-3′-glucuronide, (−)-epicatechin-3′-sulfate, 
and 3′-O-methyl-(−)-epicatechin-5-sulfate utilized transitions from 464.5 m/z to 289 m/z, 368.8 m/z to 289 m/z, 
and 382.5 m/z to 302.5 m/z, respectively with dwell times of 0.05 s, 0.1 s, and 0.1 s; cone voltages of 25 V, 30 V, and 
35 V; and collision energies of 18 V, 20 V, and 18 V respectively. Data processing was performed using Masslynx 
software (Waters). MS conditions were set by tuning with the corresponding compound. Source and desolvation 
temperature were set at 150 °C and 500 °C, respectively, while desolvation and cone gas were set at 900 L/h and 
30 L/h, respectively. In both ionization modes, capillary, cone, and lens voltage were set at 4 kV, 30 V, and 1 V, 
respectively. The identification and quantification of the compounds were based on co-elution with authentic 
standards. The precision and accuracy of the method was better than 5% and 20%, respectively.
cohort studies. We have investigated the feasibility of SREMB as nutritional biomarker of (−)-epicatechin in 
samples from two cohort studies, EPIC Norfolk and Challenge.
EPIC Norfolk. 25,639 apparently healthy men and women between 40 and 75 years of age, living in and around 
Norwich, UK, were recruited between 1993 and 199711. Spot urine samples were collected during the baseline 
health examination and stored at −20 °C; 24,341 spot urine samples were available for analysis. The study was 
approved by the Norwich District Health Authority Ethics Committee, and all participants gave signed informed 
consent.
Challenge study. 158 cognitively normal elderly people ((77 women, 81 men) aged 60 to 91 years old) living in 
and around Oxford were recruited in 1997 as part of the OPTIMA (Oxford Project to Investigate Memory and 
Ageing) study12. 24 h urine samples were collected at baseline and stored at −70 °C; 145 samples were available 
for analysis. The Central Oxford Research Ethics Committee granted ethical approval. Informed consent was 
obtained from all participants for all testing.
Statistical analyses. Associations between biomarker and intake were assessed with linear regression mod-
els using R 3.5.013 with the boot14, ggplot215 and rms16 packages. Differences between epicatechin precursors where 
investigated using one-way ANOVA with Tukey’s Honest Significant Difference method17.
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Results
Analytical method validation and performance. The analysis of nutritional biomarker requires robust 
and validated analytical methods. We have included the sum of three SREMs ((−)-epicatechin-3′-glucuronide 
(E3′G), (−)-epicatechin-3′-sulfate (E3′S) and 3′-O-methyl-(−)-epicatechin-5-sulfate (MeE5S), SREMB) in an 
LC-MS method developed for the analysis of gVLM (5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′/4′-O-glucu-
ronide (gVL34G) and 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone-3′/4′-sulfate (gVL34S)) as biomarker of fla-
van-3-ol intake, as this method can be automated and is suitable for high-throughput analysis6. The precision and 
accuracy of the method was well within the usual GLP criteria of 15% and better than 10% for most compounds. 
The estimated limit of detection (signal-to-noise ratio better than 5-to-1) was at least 0.1 µM for all compounds. 
Where matrix effects were evident, these were adequately compensated for by the use of an isotope-labelled 
internal standard. All compounds were tested for their stability in urine under different conditions, including at 
high temperature (6 h at 37 °C, 24 h at room temperature) and following four freeze-thaw cycles (−80 °C), and 
the extracted samples were tested for 72 h at 5 °C and seven days at −20 °C. All compounds were stable under 
these conditions and showed no indication of deterioration and we did not observe any batch effect or long-term 
drift of results. Table 3 shows long term precision and accuracy data for the three (−)-epicatechin metabolites 
(SREMB).
In an analysis of spot urines collected from 24,341 participants of EPIC Norfolk, biomarker concentrations 
above the limit of quantification (0.1 µmol/L) were found in 20,277 participants (83%). Figure 1 shows the distri-
bution of SREMB concentrations, which was skewed to the left with a median (IQR) of 1.2 (0.5–2.9) µmol/L and 
a mean (SD) of 2.4 (3.2) µmol/L.
Specificity of SREMB as biomarker of flavan-3-ol intake. To assess potential precursors of SREMs, 
we investigated SREMB formation following the consumption of different flavan-3-ols, including monomeric 
flavan-3-ols, oligomeric (procyanidins) and galloylated flavan-3-ols in male adults (n = 12). Figure 2 shows that 
Low QC
0.3 µM
Medium QC
2.5 µM
High QC
3.8 µM
Mean (SD) %CV %RE
Mean 
(SD) %CV %RE
Mean 
(SD) %CV %RE
(−)-epicatechin-3′-glucuronide 0.32 (0.03) 10.0 6.4 2.6 (0.3) 9.4 4.5 3.9 (0.3) 7.5 1.9
(−)-epicatechin-3′-sulfate 0.32 (0.03) 9.3 5.4 2.6 (0.2) 8.5 2.7 3.8 (0.3) 7.7 1.1
3′-O-methyl-(-)-epicatechin-5-sulfate 0.32 (0.03) 10.4 6.4 2.6 (0.2) 8.8 4.1 3.9 (0.3) 8.6 1.4
Table 3. Long term precision (%CV) and accuracy (%RE, difference of mean calculated concentration and 
nominal concentration, standardized by nominal concentration) data for the three SREMs used as biomarker 
(SREMB), based on 575 samples (except (−)-epicatechin-3′-sulfate high QC for which 370 samples only were 
available).
Figure 1. Histogram of urinary SREMB concentration in spot urines of 24,341 participants of EPIC Norfolk. 
The lower limit of quantification was 0.1 µM.
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only the consumption of (−)-epicatechin resulted in statistically significant increase of SREMB excreted in urine. 
While the intake of procyanidin dimer B2 did not statistically increase SREMB excreted in urine (p = 0.4; one-way 
ANOVA), the contribution could be estimated as 2% of the amount of procyanidin dimer B2 ingested. The rest 
of the flavan-3-ols ingested, including (−)-epicatechin-3-O-galate, did not contribute to the presence of SREMB 
excreted in urine.
Relationship between flavan-3-ol intake and SREMB. A consistent and strong relationship between 
flavan-3-ol intake and SREMB excretion in 24 h urine is crucial to establish its suitability as biomarker. We have 
therefore investigated this association with an intake-escalation study in healthy male adults (n = 14) with 
intakes of up to 1400 mg/d of flavan-3-ols (230 mg/d of (−)-epicatechin), which exceeds the range of likely die-
tary intake10,18. The results show a strong correlation between intake and SREMB (R2: 0.86 (95% CI 0.8l; 0.92), 
Spearman’s rank correlation: ρ = 0.96; Pearson’s r = 0.93; Fig. 3). These results were only slightly attenuated when 
Figure 2. Urinary excretion of structurally related (−)-epicatechin metabolites (SREMB) following the 
consumption of different flavan-3-ols in male adults (n = 12). ECG, (−)-epicatechin-3-O-gallate; DB2, 
procyanidin dimer B2; TRB: thearubigins; TF: theaflavins; EGCG, (−)-epigallocatechin-3-O-gallate; EC, 
(−)-epigallocatechin; EGC, (−)-epigallocatechin. Differences in excretion were compared using a one-way 
ANOVA and a pair-wise comparison with Tukey’s Honest Significant Difference method17.
Figure 3. Association between flavan-3-ol intake and biomarker (SREMB) excretion in male adults (n = 14). 
The data show a strong correlation between intake and biomarker (R2: 0.86 (95% CI 0.8l; 0.92)).
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excluding high intakes above 750 mg/d (R2: 0.82 (95% CI 0.73; 0.88), Spearman’s rank correlation: ρ = 0.94; 
Pearson’s r = 0.90). We also investigated the extent of the relationship between (−)-epicatechin intake and 
SREMB. The results show that the relationship between dietary intake of (−)-epicatechin and SREMB is β = 0.12 
(95% CI 0.11; 0.12) with a median recovery of 10% (IQR 7–13%).
intra- and inter-individual variability. Intra- and inter-individual variability of the association between 
flavan-3-ol intake and SREMB affect its suitability as biomarker of intake. We have therefore investigated 
intra- and inter-individual variability in men and women (n = 15, m/f: m/f) consuming 543 mg of flavan-3-ols 
(including 263 µmol (−) epicatechin) on two occasions. Mean (±SEM) SREMB excretion at the first and sec-
ond intervention was 46.2 ± 4.2 µmol and 42.8 ± 4.4 µmol respectively, with no statistically significant difference 
(paired t-test, p = 0.2). There was a strong correlation between SREMB excretion at first and second visit (Pearson’s 
ρ: 0.83; R2 = 0.66). The intra-individual variability was 12 ± 2.5%, with only two participants having differences 
larger than 20%.
Applicability of the candidate biomarker to estimate intake in free living individuals (challenge 
study). We analyzed 24 h urine (n = 158) collected in the context of the Challenge study. With a median recov-
ery of 10% as found in the intake-escalation study, the estimated intake of (−)-epicatechin was of 14.0 ± 1 mg/d, 
ranging from 0 to 58 mg/d.
Discussion
In this series of studies, we have investigated the suitability of three structurally related (−)-epicatechin 
metabolites ((−)-epicatechin-3′-glucuronide (E3′G), (−)-epicatechin-3′-sulfate (E3′S) and 3′-O-methyl-
(−)-epicatechin-5-sulfate (MeE5S), SREMB) as nutritional biomarkers of dietary (−)-epicatechin intake using 
criteria by IARC19 and the Institute of Medicine20 as described previously6. Here, we discuss whether or not 
SREMB is suitable as biomarker of flavan-3-ol intake:
Measurement of SReMB in urine using Lc-MS. The application of any biomarker relies on the avail-
ability of accurate, precise and robust analytical methods, which ideally should be suitable for automation 
and high-throughput analysis to allow their application to large studies. We have developed an analytical 
method which is suitable for the rapid analysis of the two main types of flavan-3-ol metabolites, structurally 
related (−)-epicatechin metabolites (SREM) and metabolites of the microbial fission products of flavan-3-ols, 
γ-valerolactones6. This method allows us to determine a range of different metabolites in a short time, and there-
fore is suitable for the analysis of samples even from large studies. The accurate and precise analysis of these 
metabolites requires the availability of authentic standards, as other methods, relying for example on enzymatic 
deconjugation21,22 or the identification of metabolites using their tandem-MS fragmentation pattern and quan-
tification as aglycone23, considerable bias. The measurement error introduced by these methods is dependent on 
metabolite and metabolite concentration, and therefore does not only affect absolute but also relative quantifi-
cation. This makes such methods unsuitable to rank participants according to intake, as is common practice for 
many nutritional biomarkers. We have confirmed the performance of the method following generally accepted 
standards24, with precision and accuracy well below 15% for the entire concentration range. In combination 
with a run time of eight minutes and the suitability for robotic automation, this makes the method suitable 
for the high-throughput analysis of large-scale studies. The application of the method to two different cohort 
studies in the UK shows that the validation range is sufficient to measure SREMB and gVLM23 in the majority of 
participants.
Dietary precursors of SReMB. The importance of the specificity of nutritional biomarkers has been dis-
cussed previously5,19, but in contrast to the relationship between nutritional biomarker and intake, this is not often 
assessed. We have shown that (−)-epicatechin, but none of the other flavan-3-ols tested, resulted in the formation 
of SREMB. This confirms results from our previous studies3,25, showing that oligo- and polymeric procyanidins 
are not cleaved into their flavan-3-ol subunits.
The data therefore show that urinary SREMB is specific for (−)-epicatechin, but considering that this com-
pound could be present in its enantiomeric form (+)-epicatechin, it is worth questioning whether SREMB could 
be specific to assess (−)-epicatechin intake. In this context, the biosynthetic pathways of flavonoids in plants 
result predominantly in (−)-epicatechin26 and only small amounts of (+)-epicatechin are found in the diet27 and 
thus not relevant as a contributor to SREMB. Furthermore, previous data show that (+)-epicatechin intake does 
not significantly contribute to epicatechin-3′-β-glucuronide, one of the main contributors to the set of metabolites 
included in SREMB28. Thus, SREMB will predominantly reflect the intake of (−)-epicatechin.
Association between dietary intake and SReMB. We have shown a statistically significant linear asso-
ciation between (−)-epicatechin and SREMB excretion in 24 h urine in an intake-escalation study (R2: 0.86 (95% 
CI 0.8l; 0.92)). Importantly, the association of individual metabolites showed a weaker association with intake 
than did the sum (SREMB). We demonstrated that this is due to changes in the relative contribution of different 
SREMB metabolites according to intake amount. This observation is not novel and concurs with previous studies 
demonstrating a change in sulfation/glucuronidation ratio with the amount of phenolic compounds ingested29. 
Thus, these results show that it is important to use a combination of different metabolites as biomarkers of intake, 
as changes in metabolism due to intake could result in mis-estimations of intake. The combination of metabolites 
permits both, improving the strength of the association and increasing the recovery assessed for (−)-epicatechin. 
Overall, the data presented here show that changes in urinary excretion of SREMB reflect changes in dietary 
intake of (−)-epicatechin consistently and are therefore prognostic of intake.
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Suitability of SReMB as nutritional biomarker of (−)-epicatechin intake. Our results show that 
24 h urinary SREMB excretion meets the criteria set to evaluate candidate nutritional biomarkers. Furthermore 
and according to the criterion for biomarker evaluation used previously by the NPAAS-FS (Nutrition and Physical 
Activity Assessment Study Feeding Study; R2 ≥ 0.36)30,31, the data also suggest that 24 h excretion of SREMB can 
be used as recovery biomarker of (−)-epicatechin and therefore used to estimate actual (−)-epicatechin intake. 
The correlation between intake and biomarker is >0.8 and therefore meets the criteria commonly used for recov-
ery biomarkers5. Furthermore, the data available from this and previous studies, in particular the pharmacoki-
netic data32, provide precise and quantitative knowledge of the physiological balance between intake and output 
which is required for recovery biomarkers33. In comparison with urinary nitrogen as biomarker of dietary protein 
intake, one of the best characterized recovery biomarkers, the correlations between intake and biomarker are 
comparable (0.8–0.9 for nitrogen as a biomarker of dietary protein34, 0.9 for urinary SREMB as biomarker of 
epicatechin intake). Although the recovery of (−)-epicatechin as urinary SREMB (10% ± 1%) was lower than the 
recovery of dietary nitrogen in urine (91% ± 1%34), the variability of recovery was similar and most notably the 
recovery was neither skewed nor dependent on intake. When applying this biomarker to the 24 h urine samples 
collected in Challenge, the estimated intake of (−)-epicatechin was 14.0 ± 1 mg/d, ranging from 0 to 58 mg/d.
comparison with γ-valerolactone metabolites (gVLM). We have previously evaluated gVLM as bio-
marker of flavan-3-ol intake and shown that, due to its plasma half-life of approximately 6 h32 and the frequent 
consumption of flavan-3-ol containing foods, it can be used as surrogate35 or concentration biomarker both in 
24 h urine and spot urine samples6. However, the large inter-individual variability in colonic microbial metabo-
lism makes gVLM not suitable as recovery biomarker. Conversely, the short plasma half-life of SREMB, approx-
imately 2 h, assures a complete excretion within 24 h of urine collection that, added up to the high association 
with intake, makes SREMB ideal for a recovery biomarker. Due to the different flavanols contributing to gVLM 
and SREMB and differences in half-life, the measurement of both biomarkers could provide complementary 
information. In 24 h urine samples, a combination of SREMB and gVLM could be used to differentiate between 
(−)-epicatechin and total flavan-3-ol intake, whereas in spot urine samples, SREMB can be used as marker of very 
short-term, acute (−)-epicatechin intake (see Table 4 for a direct comparison).
Strengths and limitations. This study has a number of strengths, but also some limitations which need to 
be considered when interpreting results. A key strength of the study is the carefully validated analytical method 
and the availability of authentic standards for all three (–)-epicatechin metabolites, and we have shown previously 
that this is a major contributor to the accuracy of polyphenol metabolite quantification by LC-MS23. The reliance 
on a single deuterium-labelled internal standard (D2/D3-E3′G) for quantification of E3′G, E3′S and 3′Me5S might 
have affected quantification of the latter two metabolites, but the method validation showed very good precision 
and accuracy. A further strength of the study is the careful investigation of the intake response relationship and 
in particular the specificity of SREMB. Providing the flavan-3-ol intervention on a single occasion using a defined 
test material was different from what could be expected as part of the habitual diet, but permitted a tight control 
on the amounts and type of flavan-3-ols consumed during the intervention and thus, obtain essential information 
on the specificity and intake-amount relationship of SREMB as biomarkers of (–)-epicatechin intake. A limitation 
of the study is the reliance on two UK cohorts to evaluate the applicability of SREMB as urinary biomarker. While 
flavan-3-ol intake in the UK is generally higher than in many other countries, their main source is tea10,18 with 
a very different flavan-3-ol composition than for example pome fruits. While this ensured that there was a wide 
range of flavanol intake within the study population, it could have affected outcomes. It is therefore important to 
apply this biomarker to studies from countries with more diverse sources of flavanols. Finally, it should be noted 
that the criteria chosen for the evaluation of SREMB have not been specifically created for nutritional biomarkers 
of dietary bioactives. The criteria used were derived from the frameworks provided by IARC and IOM. Future 
discussions, such as suggested previously36, are crucial to develop specific criteria for the evaluation of nutritional 
biomarkers, and thus foster the development of new biomarkers of dietary bioactives for the replacement of 
biased methods for intake assessment.
conclusion
In our studies, we have shown that 24 h urinary excretion of a combination of three structurally related 
(−)-epicatechin metabolites ((−)-epicatechin-3′-glucuronide (E3′G), (−)-epicatechin-3′-sulfate (E3′S) and 
3′-O-methyl-(−)-epicatechin-5-sulfate (MeE5S), SREMB) meet the criteria for a recovery biomarker in 24 h 
urines and can therefore be used as a nutritional biomarker to estimate actual (−)-epicatechin intake. The method 
we have developed is suitable for automation and therefore high-throughput analysis, and we have applied it suc-
cessfully to more than 24,000 samples of the EPIC Norfolk cohort. The development of this biomarker would not 
have been possible without the availability of authentic standards and detailed pharmacokinetic data.
gVLM SREMB
Sample 24 h urine, spot urine 24 h urine
Metabolites included gVL3′S, gVL3′G, gVL4′G E3′S, E3′G, 3′Me5S
Specificity Flavan-3-ol monomers, ECG, procyanidins (−)-epicatechin
Type of biomarker Concentration/surrogate recovery
Table 4. Comparison of gVLM and SREMB as biomarkers.
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We have shown that SREMB is specific for (−)-epicatechin and not any other flavan-3-ol commonly con-
sumed. Our findings provide an accurate method for the objective estimation of dietary (−)-epicatechin, the 
most likely bioactive flavan-3-ol. This opens up the possibility to investigate associations between (−)-epicatechin 
intake and health outcomes in large-scale observational studies. In the future this method could hold the poten-
tial to objectively assess dietary epicatechin adequacy as part of approaches for personalised nutrition goals.
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